{
    "status": "ok",
    "totalResults": 5,
    "articles": [
        {
            "source": {
                "id": null,
                "name": "Marketscreener.com"
            },
            "author": "Business Wire",
            "title": "Computational Fluid Dynamics (CFD) modeling further distinguishes Vapotherm High Velocity Therapy from generic high flow cannulas",
            "description": "(marketscreener.com) \nVapotherm, Inc. , a global medical technology company focused on the development and commercialization of its proprietary Vapotherm high velocity therapy\u00ae products, which are used to treat patients of all ages suffering from respiratory \u2026",
            "url": "https://www.marketscreener.com/quote/stock/VAPOTHERM-INC-47103086/news/Computational-Fluid-Dynamics-CFD-modeling-further-distinguishes-Vapotherm-High-Velocity-Therapy-fr-44980893/",
            "urlToImage": "https://www.marketscreener.com/images/twitter_MS_fdblanc.png",
            "publishedAt": "2023-10-04T10:46:02Z",
            "content": "Vapotherm, Inc. (NYSE: VAPO), a global medical technology company focused on the development and commercialization of its proprietary Vapotherm high velocity therapy\u00ae products, which are used to trea\u2026 [+7097 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "Marketscreener.com"
            },
            "author": "Business Wire",
            "title": "Pilot Study demonstrates Vapotherm HVNI technology is more effective than standard oxygen therapy for treatment of acute asthma in children",
            "description": "(marketscreener.com) \nVapotherm, Inc. , a global medical technology company focused on the development and commercialization of its proprietary Vapotherm high velocity therapy\u00ae products, which are used to treat patients of all ages suffering from respiratory \u2026",
            "url": "https://www.marketscreener.com/quote/stock/VAPOTHERM-INC-47103086/news/Pilot-Study-demonstrates-Vapotherm-HVNI-technology-is-more-effective-than-standard-oxygen-therapy-fo-44913958/",
            "urlToImage": "https://www.marketscreener.com/images/twitter_MS_fdnoir.png",
            "publishedAt": "2023-09-25T10:46:02Z",
            "content": "Vapotherm, Inc. (NYSE: VAPO), a global medical technology company focused on the development and commercialization of its proprietary Vapotherm high velocity therapy\u00ae products, which are used to trea\u2026 [+7592 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "Marketscreener.com"
            },
            "author": null,
            "title": "Vapotherm : Overview",
            "description": "(marketscreener.com) \n \n Option 5\n \n \n \n \n Certain statements in this presentation contain or may contain \"forward-looking statements\" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historic\u2026",
            "url": "https://www.marketscreener.com/quote/stock/VAPOTHERM-INC-47103086/news/Vapotherm-Overview-45042265/",
            "urlToImage": "https://www.marketscreener.com/images/twitter_MS_fdblanc.png",
            "publishedAt": "2023-10-11T16:17:05Z",
            "content": "Option 5\r\nCertain statements in this presentation contain or may contain \"forward-looking statements\" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other \u2026 [+5319 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "Biztoc.com"
            },
            "author": "benzinga.com",
            "title": "Why Biophytis Shares Are Trading Higher By Around 32%; Here Are 20 Stocks Moving Premarket",
            "description": "FaZe Holdings Inc. shares rose 64.7% to $0.2520 in pre-market trading after falling over 4% on Friday. \u2022 Biophytis S.A. shares rose 31.5% to $1.21 in pre-market trading. Biophytis and Skyepharma sign a partnership agreement for the production of Sarconeos (BI\u2026",
            "url": "https://biztoc.com/x/4709664f7f86a4ac",
            "urlToImage": "https://c.biztoc.com/p/4709664f7f86a4ac/s.webp",
            "publishedAt": "2023-09-25T13:14:12Z",
            "content": "FaZe Holdings Inc. shares rose 64.7% to $0.2520 in pre-market trading after falling over 4% on Friday.Biophytis S.A. shares rose 31.5% to $1.21 in pre-market trading. Biophytis and Skyepharma sign a \u2026 [+331 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "GlobeNewswire"
            },
            "author": "Zion Market Research",
            "title": "Global High-flow Nasal Cannula Market Size to Surpass USD 18.65 Billion Growth by 2030, Exhibit a CAGR of 12.18%",
            "description": "[228 + Pages Report] According to a market research study published by Zion Market Research, the demand analysis of Global High-flow Nasal Cannula Market size & share revenue was valued at around USD 7.45 billion in 2022 and is estimated to grow about USD 18.\u2026",
            "url": "https://www.globenewswire.com/news-release/2023/09/30/2752331/0/en/Global-High-flow-Nasal-Cannula-Market-Size-to-Surpass-USD-18-65-Billion-Growth-by-2030-Exhibit-a-CAGR-of-12-18.html",
            "urlToImage": "https://ml.globenewswire.com/Resource/Download/1f4cf0ab-7d76-4136-a6dc-a5545f80f538",
            "publishedAt": "2023-09-30T03:57:00Z",
            "content": "New York, NY, Sept. 29, 2023 (GLOBE NEWSWIRE) -- Zion Market Research has published a new research report titled High-Flow Nasal Cannula Market By End-User (Long-Term Care Centers, Hospitals, Ambulat\u2026 [+21726 chars]"
        }
    ]
}